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Abstract
Introduction: Treatment for osteomyelitis-complicating Mycobacterium ulcerans infection typically
requires extensive surgery and even amputation, with no reported benefit from adjunctive
antibiotics.
Case presentation: We report a case of an 87-year-old woman with M. ulcerans osteomyelitis
that resolved following limited surgical debridement and 6 months of therapy with rifampicin and
ciprofloxacin.
Conclusion:  M. ulcerans osteomyelitis can be successfully treated with limited surgical
debridement and adjunctive oral antibiotics.
Introduction
Mycobacterium ulcerans is the third most common myco-
bacterial disease worldwide, occurring mainly in tropical
regions. It usually causes a destructive skin and subcutane-
ous lesion, variously known as Buruli or Bairnsdale ulcer
(BU). Up to 13% of cases in Africa have been reported to
be complicated by osteomyelitis [1], however, this is rare
in Australia. Osteomyelitis is usually treated by wide sur-
gical excision, often resulting in significant morbidity.
Recently there has been some evidence to support a bene-
ficial role for antibiotics in the treatment of M. ulcerans
disease [2], including our case series on the treatment of
BU [3], but to the best of the authors' knowledge, there
have been no other reports on their benefit in treating M.
ulcerans osteomyelitis.
Case presentation
We describe a case of M. ulcerans infection from temperate
south-eastern Australia, involving six metachronous
lesions and the eventual development of osteomyelitis.
We believe this is the first reported case of M. ulcerans
osteomyelitis that was cured with a combination of minor
surgical debridement and prolonged antibiotic therapy.
A previously well 87-year-old, 55 kg woman presented
with a painless ulcer on the right calf of 3 months dura-
tion. M. ulcerans was confirmed as the aetiological agent
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by histopathology testing, showing necrotising granulo-
matous inflammation with numerous acid-fast bacilli
(AFB), a positive mycobacterial culture for M. ulcerans and
a positive polymerase chain reaction (PCR) for M. ulcerans
[4]. She was treated with wide surgical excision and pri-
mary closure, with clear histological margins.
Within 14 days, she developed a further M. ulcerans lesion
on the left heel confirmed by suggestive histology and a
positive PCR for M. ulcerans. This was treated with wide
excision and a vascularised free flap, again with clear his-
tological margins.
Despite adjunctive antibiotics (5 days of amikacin 900 mg
daily, and ongoing rifampicin 450 mg daily, ethambutol
800 mg daily and clarithromycin 250 mg twice daily), a
further lesion was found on her right buttock 25 days
later. This was excised with clear histological margins.
Although AFB were seen microscopically, and the tissue
was PCR-positive for M. ulcerans, mycobacterial cultures
were negative. At the same time, she suffered a severe
febrile drug reaction with significant malaise and dehy-
dration considered to be due to the clarithromycin. She
thus commenced on 18 days of intravenous amikacin 900
mg daily plus ongoing rifampicin 300 mg daily. Amikacin
was ceased due to ototoxicity but the rifampicin was well
tolerated.
Within 4 weeks, a further nodule was found adjacent to
the original right calf lesion and another nodule on the
right buttock. With progression of both lesions over the
following month despite the rifampicin therapy, a wide
excision of the right buttock lesion with primary closure
and clear histological margins, and a wide excision of the
right calf lesion with a skin graft were performed. One of
the histological margins of the calf lesion showed inflam-
mation and necrosis. No tissue was sent for mycobacterial
culture. She continued on rifampicin monotherapy.
An immunological screen with T-cell sub-sets, comple-
ment levels and immunoglobulin subclasses was normal,
and a myeloma screen and HIV antibody test were nega-
tive.
Four weeks later, despite continuing rifampicin mono-
therapy, a swelling was noted on the dorsum of her left
foot. This area was surgically debrided with macroscopic
evidence of involvement of the base of the first metatarsal
bone. A week later, she underwent further debridement
and removal of a bony sequestrum from the first metatar-
sal. Histopathology of the bone revealed necrotising gran-
ulomatous inflammation with numerous AFB-positive
organisms consistent with mycobacteria, however, myco-
bacterial cultures were not performed.
Over the following 2 months, she continued taking her
rifampicin 300 mg daily with initial improvement in the
foot, but then there was progression both clinically and
on computed tomography examination. Therefore, cipro-
floxacin 250 mg twice daily was added.
A magnetic resonance imaging scan performed a month
later revealed ongoing destruction of the base and
enhancement of the proximal two-thirds of the first meta-
tarsal, with now the likely involvement of the first tar-
sometatarsal joint and the medial cuneiform bone (Figure
1). She was offered further extensive surgery to attempt
removal of all infected bone but declined.
Remarkably, over the following 5 months, her wound and
sinus healed and after 6 months of combined rifampicin
and ciprofloxacin therapy, the antibiotics were ceased.
Plain X-rays repeated after 6 months, and clinical follow-
up for 36 months, revealed no evidence of persistent dis-
ease.
Sensitivity testing of her original isolate revealed it to be
sensitive to rifampicin, ethambutol, amikacin, clarithro-
mycin and ciprofloxacin.
Discussion
This case demonstrates that successful treatment of M.
ulcerans osteomyelitis and septic arthritis can be achieved
with limited surgical debridement and 6 months of oral
rifampicin and ciprofloxacin; this is, to the best of the
authors' knowledge, the first time that this has been
A magnetic resonance imaging scan of the foot showing the  destructive changes of osteomyelitis in the proximal first  metatarsal bone and adjacent medial cuneiform bone Figure 1
A magnetic resonance imaging scan of the foot show-
ing the destructive changes of osteomyelitis in the 
proximal first metatarsal bone and adjacent medial 
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reported. Our patient's osteomyelitis progressed radiolog-
ically despite initial surgical debridement, but then
resolved following the commencement of rifampicin and
ciprofloxacin without further surgery, and with no local or
distal recurrences in the 36-month follow-up period.
Thus, we believe that this combination of antibiotics
resulted in cure of the osteomyelitis in our case, and pre-
vented the development of further metachronous M.
ulcerans lesions. This raises the possibility that this simple
and well-tolerated oral combination has the potential to
reduce significantly the morbidity and disability that
results worldwide in the surgical treatment of M. ulcerans
osteomyelitis, and warrants further study.
M. ulcerans was first reported to cause osteomyelitis in
1993 [5], although recent reports suggest that it may com-
plicate skin and subcutaneous disease in up to 13% of
cases [1,6]. Usually M. ulcerans is thought to spread to
bone contiguously from the skin, although metastatic
spread via the blood stream or lymphatics has been pro-
posed [5,6]. Owing to the lack of known effective medical
treatment, surgery is usually required for cure and this
often results in amputation or severe disability [1].
The support for the effectiveness of the antibiotics in our
case is as follows. Firstly, M. ulcerans shows excellent in
vitro sensitivity to rifampicin [7], and there is evidence
from mouse models [8] and the treatment of early human
BU lesions when combined with streptomycin [2], that
rifampicin is also effective in vivo. Secondly, ciprofloxacin
has good oral bio-availability and excellent penetration
into bone and tissues, and M. ulcerans has also been
shown to be highly susceptible to it in vitro [7]. Thirdly,
the combination of rifampicin and ciprofloxacin may
have acted synergistically in our patient as there is evi-
dence in a mouse model of increased M. ulcerans bacteri-
cidal activity when rifampicin was combined with another
fluoroquinolone antibiotic, sitafloxacin [9]. Finally, we
have recently reported the benefit of adjunctive antibiotics
in surgical treatment of BU, with especially promising
results using the combination of rifampicin and cipro-
floxacin [3].
There are anecdotal reports of spontaneous resolution of
cutaneous M. ulcerans infection, but we are not aware of
this occurring once osteomyelitis has developed. Never-
theless we cannot exclude this possibility. Furthermore, as
rifampicin was used alone for 5 months prior to the com-
mencement of ciprofloxacin, and with reports of
rifampicin resistance developing when used as mono-
therapy [10], we cannot exclude the possibility that
rifampicin resistance had developed in our isolate, and
our patient responded to ciprofloxacin monotherapy.
However, this in itself is worth noting.
We would normally recommend rifampicin at a dose of
10 mg/kg daily and ciprofloxacin 500 to 750 mg twice
daily in healthy adults. However, lower doses were used in
this case to improve tolerance in view of the patient's
advanced age and frailty. Importantly, the regimen we
prescribed allowed her to complete a 6-month course,
compared with the treatment-limiting side effects she
experienced from both clarithromycin and amikacin.
This case also illustrates several important points concern-
ing the natural history and treatment of M. ulcerans infec-
tion. Firstly, M. ulcerans clearly has the potential to
disseminate, via either the haematogenous or lymphatic
route, resulting in multiple metachronous lesions, often
in quite distant parts of the body. Our patient developed
six lesions over 9 months, affecting both legs and the right
buttock.
Secondly, although wide surgical excision is usually rec-
ommended as the mainstay of treatment [11], recurrences
can occur both locally and distally. This is illustrated in
our case with the development of five recurrent lesions,
despite histology of the original excised lesion showing
clear margins.
Thirdly, despite a known sensitivity of M. ulcerans to many
drugs in vitro [7], the drugs have often not been effective
in vivo [11]. In this case, despite the original isolate show-
ing in vitro sensitivity to all the administered drugs, the
patient continued to have recurrences whilst on combina-
tions of rifampicin, clarithromycin and ethambutol; ami-
kacin and rifampicin; and rifampicin alone. Although
combinations of rifampicin and amikacin have shown
good effectiveness in mice [8], in our case, this combina-
tion over 18 days failed to prevent further recurrences.
Conclusion
M. ulcerans osteomyelitis can be successfully treated with
limited surgical debridement and 6 months of oral
rifampicin and ciprofloxacin. In addition, this antibiotic
combination may prevent progression of human M. ulcer-
ans disease. We believe that further studies evaluating this
promising antibiotic combination with more conservative
and less disabling surgery should be undertaken for both
M. ulcerans osteomyelitis and M. ulcerans disease in gen-
eral.
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